author-photo

Santosh Kumar Pandey

58

Papers

97

Citations

Citation Trend

Filter By

Papers (33) Sort By

Journal Conference Others

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT 4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease

2021 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (2)
Rhabdomyolysis and myopericarditis with renal failure in a patient of status epilepticus

2021 International Journal of Research in Medical Sciences
- Santosh Kumar Pandey
- Rajnish Avasthi
Show All
- Source
- Cite
- Save
Citations (0)
004 Samelisant (SUVN-G3031), Differentiating features over current treatments of narcolepsy

2021 Sleep
Show All
- Source
- Cite
- Save
Citations (0)
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects.

2021 Clinical Drug Investigation
Show All
- Source
- Cite
- Save
Citations (2)
SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits: Biomarkers (non‐neuroimaging)/Prognostic utility

2020 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (0)
0760 SUVN-G3031, A Potent And Selective Histamine H3 Receptor Inverse Agonist: Safety, Tolerability And Pharmacokinetics Following Single And Multiple Ascending Doses In Healthy Adult Subjects

2020 Sleep
Show All
- Source
- Cite
- Save
Citations (0)
0155 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Differentiating Features Over Current Treatments of Narcolepsy

2020 Sleep
Show All
- Source
- Cite
- Save
Citations (0)
0139 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Phase-2 Investigational New Drug for the Treatment of Narcolepsy - Differentiating Factors with Competitor Clinical Candidates

2019 Sleep
Show All
- Source
- Cite
- Save
Citations (3)
SAFETY, TOLERABILITY AND HUMAN PHARMACOKINETICS OF SUVN-502, A POTENT AND PURE 5-HT6 RECEPTOR ANTAGONIST

2019 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (0)
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects

2018 Clinical Drug Investigation
Show All
- Source
- Cite
- Save
Citations (3)